Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Ph phase_1
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedearly_phase_1

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
completedphase_1

Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)

NCT01614769
completednot_applicable

Adipose Tissue Imaging in Type 2 Diabetes

NCT02528695

Clinical Trials (3)

Showing 3 of 3 trials
NCT02398383Early Phase 1

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

Completed
NCT01614769Phase 1

Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)

Completed
NCT02528695Not Applicable

Adipose Tissue Imaging in Type 2 Diabetes

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3